Knight Therapeutics (TSE:GUD) Trading Down 0.7% – What’s Next?

Knight Therapeutics Inc. (TSE:GUD)’s stock price traded down 0.7% during mid-day trading on Monday . The company traded as low as C$6.04 and last traded at C$6.09. 82,521 shares were traded during trading, an increase of 25% from the average session volume of 66,027 shares. The stock had previously closed at C$6.13.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Canaccord Genuity Group set a C$6.50 target price on Knight Therapeutics and gave the company a “buy” rating in a research report on Friday, May 9th. Stifel Nicolaus increased their target price on Knight Therapeutics from C$6.25 to C$7.45 and gave the company a “buy” rating in a research report on Tuesday, March 25th. Two equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Strong Buy” and an average price target of C$7.15.

Knight Therapeutics Trading Down 0.7%

The company has a 50 day moving average of C$5.90 and a 200 day moving average of C$5.77. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The stock has a market capitalization of C$616.00 million, a price-to-earnings ratio of -20.33, a P/E/G ratio of -1,013.50 and a beta of 0.50.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.